Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunovant (DE:4YB)
STUTTGART:4YB
Immunovant (4YB) Stock Price & Analysis
0 Followers
4YB Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Immunovant News
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageImmunovant has a first-mover advantage in the thyroid/endocrine space with clear unmet needs for novel mechanisms of action.
Drug Development And Market PotentialManagement is bullish on the company's positioning in the FcRn/IgG space and future development of IMVT-1402 for best-in-class and first-in-class indications.
Financial PerformancePeak sales for IMVT-1402 could reach $4.4B with efficacy in line with advanced candidates, and there's an upside potential for $6.2B in peak sales pending best-in-class efficacy.
Bears Say
Clinical TrialsManagement highlighted concerns over potential risks associated with >85% IgG reduction, such as infection risk and stopping rules for trials.
Competitive PositionA pipeline competitor is expected to report potentially competitive data, which could pose a risk to Immunovant's market position.
Financial StabilityImmunovant has a significant annual cash burn rate, which may impact its financial stability in the absence of additional funding or revenues.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.26% Other Institutional Investors
99.74% Public Companies and
Individual Investors
4YB FAQ
What was Immunovant’s price range in the past 12 months?
Currently, no data Available
What is Immunovant’s market cap?
Currently, no data Available
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Jul 01, 2024 which is in 59 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Feb 12, 2024. The company reported -€0.27 earnings per share for the quarter, beating the consensus estimate of -€0.403 by €0.133.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -€0.4.
How many shares outstanding does Immunovant have?
Currently, no data Available
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -€0.27 in its last earnings report, beating expectations of -€0.403. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Immunovant?
Among the largest hedge funds holding Immunovant’s share is Perceptive Advisors LLC. It holds Immunovant’s shares valued at 98M.
---
Immunovant Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€47.97 (― Upside)
€47.97 (― Upside)
Blogger Sentiment
Bullish
DE:4YB Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $3.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
61.86%
12-Months-Change
Fundamentals
Return on Equity
-44.51%
Trailing 12-Months
Asset Growth
55.94%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.
---
4YB Stock 12 Months Forecast
Average Price Target
―Immunovant
―
Kala Pharmaceuticals
―
Adverum Biotechnologies
―
Arvinas Holding Company
―
RAPT Therapeutics
―
Best Analysts Covering 4YB
1 Year
1 Year Success Rate
11/20 ratings generated profit
1 Year Average Return
+65.59%
reiterated a buy rating 3 months ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 55.00% of your transactions generating a profit, with an average return of +65.59% per trade.
---